Loading...
•
Mar 31, 2023
Scholar Rock Q1 2023 Earnings Report
Scholar Rock reported financial results for Q1 2023 and provided corporate updates.
Key Takeaways
Scholar Rock reported a net loss of $39.4 million, with $0 revenue for the quarter ended March 31, 2023. The company had approximately $275 million in cash, cash equivalents, and marketable securities as of March 31, 2023, which is expected to fund operations into 2025.
Pivotal Phase 3 SAPPHIRE trial evaluating apitegromab is on track for completion in 2023.
36-month apitegromab data from Phase 2 TOPAZ trial will be presented at Cure SMA's Annual Research & Clinical Conference.
Phase 1 DRAGON trial of SRK-181 is advancing, with a biomarker and clinical data update planned in the second half of 2023.
Cash, cash equivalents, and marketable securities were approximately $275 million as of March 31, 2023, expected to fund operations into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...